Aegirbio AB
STO:AEGIR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Aegirbio AB
Total Current Liabilities
Aegirbio AB
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Aegirbio AB
STO:AEGIR
|
Total Current Liabilities
kr10.4m
|
CAGR 3-Years
31%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Total Current Liabilities
kr199.1m
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Total Current Liabilities
kr164.3m
|
CAGR 3-Years
22%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Total Current Liabilities
kr615m
|
CAGR 3-Years
0%
|
CAGR 5-Years
28%
|
CAGR 10-Years
17%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Total Current Liabilities
kr16.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
9%
|
CAGR 10-Years
28%
|
|
|
BioArctic AB
STO:BIOA B
|
Total Current Liabilities
kr520.8m
|
CAGR 3-Years
94%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
Aegirbio AB
Glance View
AegirBio AB engages in the development and commercialization of drug monitoring tests. The company is headquartered in Lund, Skane. The company went IPO on 2020-06-26. The firm offers tests to monitor and optimize the dosage of biological drugs via its patented technology platform. The company aims to provide personalized treatment by tracking drugs levels in individuals. Aegirbio combines core technologies from LifeAssays and Abreos Biosciences. LifeAssays is a diagnostics company based in Sweden, which owns the Magnia Point of Care and Point of Need reader technology. Abreos Biosciences is a California-based biotech, which is a developer of the Veritope chemistry platform for detecting levels of biologic drugs in patient samples.
See Also
What is Aegirbio AB's Total Current Liabilities?
Total Current Liabilities
10.4m
SEK
Based on the financial report for Dec 31, 2023, Aegirbio AB's Total Current Liabilities amounts to 10.4m SEK.
What is Aegirbio AB's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 3Y
31%
Over the last year, the Total Current Liabilities growth was -40%. The average annual Total Current Liabilities growth rates for Aegirbio AB have been 31% over the past three years .
